Fludeoxyglucose
As of the edition of 20 October 2026, Fludeoxyglucose is a small molecule: marketed, first approved in 1994 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Small molecule
- Brand name
- 18F-FDG-FR
- First approved
- 19 August 1994 (US)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Feinstein Institute Medical; 6 holders in all
- Registered trials
- 168, 19 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Immune system; Blood and lymph; Heart and blood vessels
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 47 | 20 | 15 | 3 |
| Phase 1 | 49 | 8 | 27 | 8 |
| Phase 2 | 53 | 16 | 27 | 6 |
| Phase 3 | 12 | 1 | 11 | 0 |
| Phase 4 | 7 | 1 | 3 | 2 |
| All trials | 168 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Downstate Clinical Pet Center | Acquired holder | 2003 to now |
| Weill Medical College Cornell Univ | Later holder | 2004 to now |
| Nihon Medi-Physics | Applicant | 2005 to now |
| Feinstein Institute Medical | Acquired holder | 2008 to now |